Entasis Therapeutics Holdings (Entasis Therapeutics Holdings) Change In Receivables : $1.41 Mil (TTM As of Mar. 2022)

View and export this data going back to 2018. Start your Free Trial

What is Entasis Therapeutics Holdings Change In Receivables?

Entasis Therapeutics Holdings's change in receivables for the quarter that ended in Mar. 2022 was $0.11 Mil. It means Entasis Therapeutics Holdings's Accounts Receivable declined by $0.11 Mil from Dec. 2021 to Mar. 2022 .

Entasis Therapeutics Holdings's change in receivables for the fiscal year that ended in Dec. 2021 was $0.63 Mil. It means Entasis Therapeutics Holdings's Accounts Receivable declined by $0.63 Mil from Dec. 2020 to Dec. 2021 .

Entasis Therapeutics Holdings's Accounts Receivable for the quarter that ended in Mar. 2022 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Entasis Therapeutics Holdings's liquidation value for the three months ended in Mar. 2022 was $6.10 Mil.

Entasis Therapeutics Holdings Change In Receivables Historical Data

The historical data trend for Entasis Therapeutics Holdings's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entasis Therapeutics Holdings Change In Receivables Chart

Entasis Therapeutics Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Change In Receivables

Get a 7-Day Free Trial

-0.72

-0.98

0.47

-0.66

0.63

Entasis Therapeutics Holdings Quarterly Data
	Dec16	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Change In Receivables	Get a 7-Day Free Trial															-0.67	-0.10	-0.31	1.71	0.11

Entasis Therapeutics Holdings Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.41 Mil.

Entasis Therapeutics Holdings (NAS:ETTX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Entasis Therapeutics Holdings's Days Sales Outstanding for the quarter that ended in Mar. 2022 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Entasis Therapeutics Holdings's accounts receivable are only considered to be worth 75% of book value:

Entasis Therapeutics Holdings's liquidation value for the quarter that ended in Mar. 2022 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	33.547	-	27.443	+	0.75 * 0	+	0.5 * 0
=	6.10

Entasis Therapeutics Holdings Change In Receivables Related Terms

Thank you for viewing the detailed overview of Entasis Therapeutics Holdings's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Entasis Therapeutics Holdings (Entasis Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entasis Therapeutics Holdings Inc (NAS:ETTX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

35 Gatehouse Drive, Waltham, MA, USA, 02451

Website

https://www.entasistx.com

Entasis Therapeutics Holdings Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. The company's pathogen-targeted design platform has produced a pipeline of product candidates, including SUL-DUR (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacterales infections) and ETX0462 (targeting Gram-negative infections including Pseudomonas).

Executives

Theravance Inc	10 percent owner	1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Kristie Ann Wagner	officer: VP, Principal Fin & Acct Off	35 GATEHOUSE DRIVE WALTHAM MA 02451
David Altarac	officer: Chief Medical Officer	35 GATEHOUSE DRIVE WALTHAM MA 02451
Michael Gutch	officer: Chief Fin. and Bus. Officer	C/O ALBIREO PHARMA, INC., 50 MILK STREET, 16TH FLOOR, BOSTON MA 02109
John Patrick Mueller	officer: Chief Development Officer	C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Manoussos Perros	director, officer: President and CEO	C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Ruben Tommasi	officer: Chief Scientific Officer	C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Matthew Ronsheim	officer: See Remarks	35 GATEHOUSE DRIVE WALTHAM MA 02451
Elizabeth M Keiley	officer: General Counsel	C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Anna Diaz Triola	officer: Chief Commercial Officer	35 GATEHOUSE DRIVE WALTHAM MA 02451
Innoviva Strategic Opportunities Llc	director, 10 percent owner	1209 ORANGE STREET, WILMINGTON DE 19801
Eric Wilson Kimble	officer: Chief Commercial Officer	C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Frazier Life Sciences Viii, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Howard Mayer	director	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Heather Behanna	director	C/O ENTASIS THERAPEUTICS HOLDINGS INC., 35 GATEHOUSE DRIVE, WALTHAM MA 02451